Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 6, 2011, Pages 767-773

  Serakinci, Nedime ^a,b   Christensen, Rikke ^c,d   Fahrioglu, Umut ^b   Sorensen, Flemming Brandt ^e   Dagnæs Hansen, Frederik ^d   Hajek, Miroslav ^a   Jensen, Tinna Herløv ^e   Kolvraa, Steen ^e   Keith, Nicol W ^f  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b NEAR EAST UNIVERSITY   (Turkey)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e LILLEBAELT HOSPITAL   (Denmark)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cancer; delivery vehicles; mesenchymal stem cells; telomerase; therapeutic delivery

Indexed keywords

CISPLATIN; TELOMERASE; TRETAZICAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL HOMING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FIBROBLAST; GENETIC ENGINEERING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENETIC ENGINEERING; HUMANS; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; OVARIAN NEOPLASMS; STROMAL CELLS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83455262982     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1024     Document Type: Article

References (45)

1. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994;56:283.
2. Caplan AI. The mesengenic process. Clin Plast Surg 1994;21:429.
3. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999;96:10711.
4. Kuznetsov SA, Friedenstein AJ, Robey PG. Factors required for bone marrow stromal fibroblast colony formation in vitro. Br J Haematol 1997;97:561.
5. Kuznetsov SA, Krebsbach PH, Satomura K, et al. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997;12:1335.
6. Prockop DJ. Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 1997;276:71.
7. Abdallah BM, Ditzel N, Kassem M. Assessment of bone formation capacity using in vivo transplantation assays: Procedure and tissue analysis. Methods Mol Biol 2008;455:89.
8. De Bari C, Dell'Accio F, Tylzanowski P, et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001;44:1928.
9. Gronthos S, Zannettino AC, Hay SJ, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003;116:1827.
10. Morikawa S, Mabuchi Y, Niibe K, et al. Development of mesenchymal stem cells partially originate from the neural crest. Biochem Biophys Res Commun 2009;379:1114.
11. Peault B, Rudnicki M, Torrente Y, et al. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007;15:867.
12. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143.
13. Simonsen JL, Rosada C, Serakinci N, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002;20:592.
14. Tsai MS, Lee JL, Chang YJ, et al. Isolation of human multi-potent mesenchymal stem cells from second-trimester am-niotic fluid using a novel two-stage culture protocol. Hum Reprod 2004;19:1450.
15. Johnstone B, Yoo JU. Autologous mesenchymal progenitor cells in articular cartilage repair. Clin Orthop Relat Res 1999;367(Suppl):S156.
16. Richards M, Huibregtse BA, Caplan AI, et al. Marrow-derived progenitor cell injections enhance new bone formation during distraction. J Orthop Res 1999;17:900.
17. Weissman IL. Translating stem and progenitor cell biology to the clinic: Barriers and opportunities. Science 2000;287:1442.
18. Young RG, Butler DL, Weber W, et al. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res 1998;16:406.
19. Matthay MA, Goolaerts A, Howard JP, et al. Mesenchymal stem cells for acute lung injury: Preclinical evidence. Crit Care Med 2010;38:S569.
20. Momin EN, Vela G, Zaidi HA, et al. The oncogenic potential of mesenchymal stem cells in the treatment of cancer: Directions for future research. Curr Immunol Rev 2010;6:137.
21. Volarevic V, Arsenijevic N, Lukic ML, et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 2011;29:5.
22. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the in-farcted myocardium: Feasibility, cell migration, and body distribution. Circulation 2003;108:863.
23. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932.
24. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98:10344.
25. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleo-mycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407.
26. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004;95:9.
27. Mittal S, Mifflin R, Powell DW. Cancer stem cells: The other face of Janus. Am J Med Sci 2009;338:107.
28. Sullivan NJ, Hall BM. Mesenchymal stem cells in tumor stroma. In: Bagley RG, Teicher BA, eds. Cancer Drug Discovery and Development: Stem Cells and Cancer, Part 2. Humana Press, Farmingham, MA. 2009;27.
29. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593.
30. Seo SH, Kim KS, Park SH, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011;18:488.
31. Serakinci N, Christensen R, Graakjaer J, et al. Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart. Exp Cell Res 2007;313:1056.
32. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitro-reductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001;20:7797.
33. Bentzon JF, Stenderup K, Hansen FD, et al. Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene. Biochem Biophys Res Commun 2005;330:633.
34. Shabbir A, Zisa D, Leiker M, et al. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: Muscle regeneration without immunosuppression and inflammation. Transplantation 2009;87:1275.
35. Patel SA, Ndabahaliye A, Lim PK, et al. Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (London) 2010;2:1.
36. Kortesidis A, Zannettino A, Isenmann S, et al. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 2005;105:3793.
37. Von Luttichau I, Notohamiprodjo M, Wechselberger A, et al. Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 2005;14:329.
38. Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643.
39. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009;27:2320.
40. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603.
41. Placencio VR, Li X, Sherrill TP, et al. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS One 2010;5:e12920.
42. Wang Y, Huso DL, Harrington J, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005;7:509.
43. Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcrip-tional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000;2:539.
44. Bilsland AE, Fletcher-Monaghan A, Keith WN. Properties of a telomerase-specific Cre/Lox switch for transcrip-tionally targeted cancer gene therapy. Neoplasia 2005;7: 1020.
45. Komata T, Koga S, Hirohata S, et al. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 2001;19: 1015.